ArticlePhenomics (Cham, Switzerland)2023
Proteomic Portrait of Human Lymphoma Reveals Protein Molecular Fingerprint of Disease Specific Subtypes and Progression.
Article in Phenomics (Cham, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Associations between genetically predicted concentrations of plasma proteins and the risk of prostate cancer.BMC cancer · 2024Pooled it
- Pacemaker implantation is associated with post-ablation atrial fibrillation recurrence mediated by plasma CILP1.Scientific reports · 2026Article
- Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC.Journal of hematology & oncology · 2025Article
- Enhancing allergy diagnosis: mass spectrometry as a complementary technique to the basophil activation test.Frontiers in allergy · 2025Review
- Progress of the Impact of Terahertz Radiation on Ion Channel Kinetics in Neuronal Cells.Neuroscience bulletin · 2024Review
- Reference Materials for Improving Reliability of Multiomics Profiling.Phenomics (Cham, Switzerland) · 2024Review
- STAVER: a standardized benchmark dataset-based algorithm for effective variation reduction in large-scale DIA-MS data.Briefings in bioinformatics · 2024Article
- Proteogenomic insights into the biology and treatment of pan-melanoma.Cell discovery · 2024Article
- SEAOP: a statistical ensemble approach for outlier detection in quantitative proteomics data.Briefings in bioinformatics · 2024Article
- Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma.Nature communications · 2024Article
- Proteome profiling of early gestational plasma reveals novel biomarkers of congenital heart disease.EMBO molecular medicine · 2023Article
- Plasma proteomic profiling discovers molecular features associated with upper tract urothelial carcinoma.Cell reports. Medicine · 2023Article
- Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An altered proteome in lymph nodes often suggests abnormal signaling pathways that may be associated with diverse lymphatic disorders. Current clinical biomarkers for histological classification of lymphomas have encountered many discrepancies, particularly for borderline cases. Therefore, we launched a comprehensive proteomic study aimed to establish a proteomic landscape of patients with various lymphatic disorders and identify proteomic variations associated with different disease subgroups. In this study, 109 fresh-frozen lymph node tissues from patients with various lymphatic disorders (with a focus on Non-Hodgkin's Lymphoma) were analyzed by data-independent acquisition mass spectrometry. A quantitative proteomic landscape was comprehensively characterized, leading to the identification of featured protein profiles for each subgroup. Potential correlations between clinical outcomes and expression profiles of signature proteins were also probed. Two representative signature proteins, phospholipid-binding proteins Annexin A6 (ANXA6) and Phospholipase C Gamma 2 (PLCG2), were successfully validated via immunohistochemistry. We also evaluated the capability of acquired proteomic signatures to segregate multiple lymphatic abnormalities and identified several core signature proteins, such as Sialic Acid Binding Ig Like Lectin 1 (SIGLEC1) and GTPase of immunity-associated protein 5 (GIMAP5). In summary, the established lympho-specific data resource provides a comprehensive map of protein expression in lymph nodes during multiple disease states, thus extending the existing human tissue proteome atlas. Our findings will be of great value in exploring protein expression and regulation underlying lymphatic malignancies, while also providing novel protein candidates to classify various lymphomas for more precise medical practice. Supplementary Information: The online version contains supplementary material available at 10.1007/s43657-022-00075-w.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.